Please check your internet connection and try again.
# Hyaluronic acid
## Overview
Hyaluronic acid (HA) is a naturally occurring high-molecular-weight glycosaminoglycan found in connective tissue, skin, and synovial fluid. Clinical formulations are used for intra-articular supplementation (viscosupplementation), ophthalmic procedures, and topically for wound healing or dermatologic aesthetics.
## Primary Indications
* **Osteoarthritis (OA) of the knee:** Pain management in patients failing conservative therapy.
* **Ophthalmic surgery:** Maintaining anterior chamber depth (viscoelastic agent).
* **Dermatology:** Dermal filler for tissue augmentation; topical moisturizer for wound care.
## Adult Dosing
* **Intra-articular (Knee OA):** Dosing and frequency vary significantly by specific product (e.g., Hyalgan, Synvisc, Euflexxa).
* **Common regimen:** 2 mL (10–20 mg per mL) injected intra-articularly once weekly for 3 to 5 weeks.
* **Single-injection products (e.g., Durolane):** 60 mg (3 mL) as a single intra-articular injection.
* **Note:** Always consult the specific product package insert, as dosing is non-interchangeable between brands.
## Pediatric Dosing
Safety and efficacy are not established for intra-articular use in patients <18 years. Use is generally restricted to ophthalmic surgery per surgeon discretion under specialized protocols.
## Dose Adjustments
* **Renal/Hepatic impairment:** No specific adjustments required for intra-articular or topical administration.
* **Geriatric:** Use cautiously in patients with known inflammatory joint conditions or active infections.
## Contraindications
* **Allergy:** Known hypersensitivity to hyaluronan preparations or avian proteins (for products derived from avian sources).
* **Infection:** Active joint infection, skin disease, or infection in the area of the injection site.
* **Known systemic bleeding disorders** (for intra-articular use).
## Adverse Effects
* **Intra-articular:** Injection site pain, joint swelling/effusion, arthralgia, pruritus, and rarely, pseudoseptic arthritis (acute inflammatory reaction).
* **Ophthalmic:** Transient increased intraocular pressure.
* **Dermal:** Bruising, erythema, edema, or nodules at the injection site.
## Key Drug Interactions
There are no clinically significant systemic drug-drug interactions, as hyaluronic acid is not absorbed systemically in meaningful quantities via intra-articular or topical routes. Avoid concomitant intra-articular injection of quaternary ammonium salts (e.g., benzalkonium chloride), as they may cause HA to precipitate.
## Monitoring
* **Post-Injection:** Monitor for acute joint swelling, pain, or symptoms suggestive of septic arthritis (fever, systemic chills) within the first 48 hours.
* **Efficacy:** Assess pain levels and joint range of motion 4–8 weeks post-completion of the injection cycle.
## Clinical Pearls
* **Variable Efficacy:** Meta-analyses show variable results for knee OA; clinicians should manage patient expectations regarding the time to onset (often 4+ weeks) and duration of benefit (up to 6 months).
* **Source Sensitivity:** Ensure patients are screened for egg or avian protein allergies if using avian-derived products.
* **Injection Technique:** Intra-articular administration must be performed under strict aseptic conditions. Use of ultrasound guidance is recommended to ensure intra-articular placement.
* **Storage:** Most commercially available intra-articular syringes must be stored at controlled room temperature and protected from freezing.
***
**Educational Disclaimer:** This information is for educational purposes only. Specific dosing, frequency, and product selection depend on local institutional protocols and individual product labels. Always verify the current prescribing information and the specific product manufacturer's guidelines before administration.
